<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35601270</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2514-1775</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Rheumatology advances in practice</Title>
          <ISOAbbreviation>Rheumatol Adv Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient.</ArticleTitle>
        <Pagination>
          <StartPage>rkac032</StartPage>
          <MedlinePgn>rkac032</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">rkac032</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/rap/rkac032</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Valor-Méndez</LastName>
            <ForeName>Larissa</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-4872-3502</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine 3, Rheumatology and Immunology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manger</LastName>
            <ForeName>Bernhard</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-2375-0069</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine 3, Rheumatology and Immunology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wacker</LastName>
            <ForeName>Jochen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine 3, Rheumatology and Immunology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleyer</LastName>
            <ForeName>Arnd</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine 3, Rheumatology and Immunology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schett</LastName>
            <ForeName>Georg</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine 3, Rheumatology and Immunology.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Rheumatol Adv Pract</MedlineTA>
        <NlmUniqueID>101736676</NlmUniqueID>
        <ISSNLinking>2514-1775</ISSNLinking>
      </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>4</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35601270</ArticleId>
        <ArticleId IdType="pmc">PMC9115673</ArticleId>
        <ArticleId IdType="doi">10.1093/rap/rkac032</ArticleId>
        <ArticleId IdType="pii">rkac032</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
McInnes IB, Anderson JK, Magrey M. 
et al.
Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021;384:1227–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33789011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cohen SB, Tanaka Y, Mariette X. 
et al.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5530353</ArticleId>
            <ArticleId IdType="pubmed">28143815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Winthrop KL, Park SH, Gul A. 
et al.
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4893093</ArticleId>
            <ArticleId IdType="pubmed">26318385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smolen JS, Genovese MC, Takeuchi T. 
et al.
Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019;46:7–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30219772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D.. 
Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020;19:861–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32552289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Genovese MC, Fleischmann R, Combe B. 
et al.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018;391:2513–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29908670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coltro G, Vannucchi AM.. 
The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opin Drug Saf 2021;20:139–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33327810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cantini F, Nannini C, Niccoli L. 
et al.
Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017;2017:8909834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5474286</ArticleId>
            <ArticleId IdType="pubmed">28659665</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
